Total amount raised
Latest funding date

Location


Jon Resnick is the CEO of Certara, a company specializing in biosimulation software and services for the biotechnology and pharmaceutical industries. A healthcare executive with a proven track record of building transformational businesses, Resnick brings deep expertise in leading global teams, leveraging data and technology, and delivering on strategic vision through innovative, scalable solutions.
Who is the CEO of Certara?
Jon Resnick, CEO of Certara since January 2026, is a seasoned healthcare executive with extensive experience building transformational businesses. He is adept at leading global teams to deliver on a strategic vision by anticipating market needs and identifying innovative, scalable solutions. Resnick has dedicated his career to addressing cross-stakeholder challenges through solutions that leverage data, technology, advanced analytics, and new scientific methodologies.
Prior to joining Certara, Resnick held senior leadership roles at IQVIA, where he served as President of the United States and Canada and, before that, as President of Real World & Analytics Solutions. Earlier in his career, he served on the Professional Health and Social Security Staff for the Committee on Finance in the United States Senate.
Work History
- Certara, CEO (January 2026 - Present)
- IQVIA, President, United States and Canada (July 2019 - December 2025)
- IQVIA, President, Real World & Analytics Solutions (January 2018 - June 2019)
- United States Senate, Professional Health and Social Security Staff, Committee on Finance (January 1996 - June 2000)
Education History
Jon Resnick attended Northwestern University's Kellogg School of Management, one of the world's leading business schools known for developing collaborative, innovative leaders.
When did Jon Resnick join Certara?
Jon Resnick assumed the role of CEO at Certara in January 2026, bringing with him a wealth of experience from senior leadership positions across the healthcare industry, including his tenure at IQVIA and earlier work in public policy on Capitol Hill.


























